MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on May 20, 2008; DOI: 10.1124/mol.108.048991

0026-895X/08/7402-309-311$20.00
Mol Pharmacol 74:309-311, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.108.048991v1
74/2/309    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Evers, R.
Right arrow Articles by Chu, X.-Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evers, R.
Right arrow Articles by Chu, X.-Y.
Perspective

Role of the Murine Organic Anion-Transporting Polypeptide 1b2 (Oatp1b2) in Drug Disposition and Hepatotoxicity

Raymond Evers, and Xiao-Yan Chu

Drug Metabolism and Pharmacokinetics, Global Technologies, Merck & Co, Inc., Rahway, New Jersey

Several members of the organic anion transporting polypeptide (OATP/Oatp) family of uptake transporters are expressed in the hepatocyte sinusoidal membrane in humans and preclinical species. The mouse liver specific Oatp is Oatp1b2, and the human homologs most closely related are OATP1B1 and 1B3. The substrate specificity of these transporters is broad, and the widely accepted view is that they play an important role in drug disposition. However, direct evidence that OATP/Oatps are important for drug disposition in vivo has been lacking thus far. In this issue of Molecular Pharmacology, Zaher et al. (p. 320), along with Lu et al. (Toxicol Sci 103: 35-45, 2008)[Abstract/Free Full Text] , report on the characterization of mice with a targeted disruption of the organic anion transporting polypeptide Oatp1b2. The Oatp1b2(-/-) mice were viable and fertile and did not demonstrate obvious phenotypic abnormalities. Zaher et al. performed a pharmacokinetic analysis with the human OATP1B1 and -1B3 substrates rifampicin and pravastatin and demonstrated a reduced liver-to-plasma ratio for these drugs in knockout compared with control mice, providing strong evidence that Oatp1b2 played an important role in the disposition of these drugs. Lu et al. found that the Oatp1b2(-/-) mice were completely resistant to hepatoxicity induced by phalloidin and microcystin-LR. Taken together, these data illustrate that Oatp1b2(-/-) mice are an important new model to investigate the role of this transporter in drug disposition and hepatotoxicity.

Received May 19, 2008; accepted May 20, 2008

Address correspondence to: Dr. Raymond Evers, Drug Metabolism and Pharmacokinetics, Merck and Co Inc., RY80-141, 126 E. Lincoln Ave., Rahway, NJ 07065. E-mail: raymond_evers{at}merck.com


Related articles in MolPharm:

Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin
Hani Zaher, Henriette E. Meyer zu Schwabedissen, Rommel G. Tirona, Melissa L. Cox, Leslie A. Obert, Nidhi Agrawal, Joe Palandra, Jeffrey L. Stock, Richard B. Kim, and Joseph A. Ware
MolPharm 2008 74: 320-329. [Abstract] [Full Text]  





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics